Home
About
Jobs
Programs
Community
Providers
Boards
Regulatory
Resources
Contact
Media

Technical Bulletins - COVID-19

COVID-19

FDA Approves and Authorizes for Emergency Use Updated COVID-19 Vaccines and De-authorizes Administration of 2023-2024 COVID-19 Vaccines 
2023-2024 COVID-19 Vaccine Recommendations
Updated COVID-19 Infection Prevention and Control Guidance for Health Care Personnel
FDA Ends Monovalent mRNA Authorization and Simplifies Use of Bivalent COVID-19 Vaccines
Bivalent COVID-19 Vaccines Now Authorized for Expansion in 6 months and Older
Discontinuation of Reporting COVID-19 Negative Laboratory Results
Adverse Event Reporting Following COVID-19 Vaccination
Bivalent COVID-19 Vaccines Now Authorized for individuals 6 months of Age and Older
Novavax COVID-19 Vaccine, Adjuvanted Booster Now Authorized for 18+
Bivalent COVID-19 Booster Vaccine Recommended for 5 Years and Older
Updated Infection Prevention and Control Recommendations for Health Care Personnel During the Coronavirus Disease (COVID-19) Pandemic
Novavax COVID-19 Vaccine, Adjuvanted, Now Recommended by CDC for 12+ Years
Updated Guidance: What To Do When Exposed to COVID-19
Bivalent COVID-19 Booster Vaccine Recommended for 12 Years and Older
Updated Guidance: Isolation and Precautions for People with COVID-19
Novavax COVID-19 Vaccine, Adjuvanted Authorized for Emergency Use Authorization
Moderna COVID-19 Vaccine Approved for Children and Adolescents 6 – 17 years
Pediatric COVID-19 Vaccines Recommended for Children Aged 6 months – 5 years
Pfizer-BioNTech COVID-19 Vaccine Booster Dose for Children 5-11 Years
COVID-19 Vaccine Additional Booster Dose Recommendations
Updates to COVID-19 Laboratory Reporting Requirements
Updated Interim Clinical Considerations for COVID-19 Vaccine Use
Mask Mitigation Requirements for Licensed Health Care Facilities
Updated Quarantine Guidance - Jan. 31, 2022
Developing and maintaining written plans that balance access to care, staffing shortages and infection control
Updated Quarantine Guidance - Jan. 18, 2022
COVID-19 Vaccine Updated Booster Dose Recommendations
Update to COVID-19 Point of Care Antigen Testing in Community Settings
Public Health Considerations for COVID-19 At-Home Test Kit
Updated COVID-19, Influenza and RSV
Updated Quarantine Guidance
Updated Guidance for Discontinuation of COVID-19 Isolation
Preferential Recommendations for mRNA COVID-19 Vaccines
- Recomendaciones Preferentes para vacunas ARNm contra COVID-19
COVID-19 Vaccine Booster Doses for 16-17-year-olds
- Dosis de refuerzo de la vacuna Covid-19 para jóvenes de 16-17 años
COVID-19 Vaccine Booster Dose Recommendations for Adults and Emergency Use Instructions
- Boletín Técnico de la Programa de Inmunización del Estado de Nevada - Recomendaciones de dosis de refuerzo de la vacuna Covid-19 para adultos e instrucciones de uso en caso de emergencia
Clinical considerations for administering Pfizer-BioNTech COVID-19 vaccine to children ages 5-11 years
COVID Vaccine Booster Doses for Janssen/Johnson & Johnson (J&J) and Moderna
Clinical Laboratory Submission to State and Local Public Health Laboratories
Update: COVID-19 Point of Care Antigen Testing in Community Settings
COVID-19, Influenza and Respiratory Syncytial Virus (RSV)
Pfizer-BioNTech COVID-19 Vaccine Booster Recommendations
Quarantine new admits and readmissions regardless of vaccination status in nursing homes and residential facilities
- Poner en cuarentena a los nuevos ingresos y a los reingresos, independientemente del estado de vacunacion en las residencias de ancianos e instalaciones residenciales.
Updated Tuberculosis (TB) Testing Recommendations Around COVID-19 Vaccinations
- Recomendaciones actualizadas para las pruebas de tuberculosis (TB) en torno a las vacunas COVID-19
Regulatory Updates for COVID-19 Vaccines – U.S. Food and Drug Administration Approves Licensure of the Pfizer-BioNTech COVID-19 Vaccine
Recommendations for COVID-19 Vaccination for People Who are Pregnant or Breastfeeding
- Recomendaciones para la vacuna contra COVID-19 para Personas Embarazadas o Mujeres bajo lactancia
Additional mRNA COVID-19 Dose Recommended for Moderately and Severely Immunocompromised Individuals
- Dosis adicional de ARNm contra COVID-19 recomendada para individuos con inmunodepresión moderada o grave
COVID-19 Data Reporting Requirement for Skilled Nursing Facilities
Updated Tuberculosis (TB) Testing Interim Recommendations Around COVID-19 Vaccinations
COVID-19 Sequencing Update - Clinical Laboratories to Submit all Positive SARS-CoV-2 Samples to the Nevada State Public Health Laboratory
- Actualización de la secuenciación de COVID-19 - Los laboratorios clínicos deben enviar todas las muestras positivas de SARS-CoV-2 al laboratorio de salud pública del estado de Nevada
ACIP Discussions on Myocarditis Post-COVID 19 Vaccination and Potential Need for COVID-19 Booster Doses
- Debates del ACIP sobre la miocarditis después de la vacunación con COVID 19 y la posible necesidad de dosis de refuerzo de COVID-19
Monitoring Reports of Myocarditis Post-COVID-19 Vaccination
- Informes de Seguimiento sobre Miocarditis Post Vacuna COVID-19
Public Health Considerations for COVID-19 At-Home Test Kits
- Consideraciones de Salud Publica para los Kits de Prueba Casera para COVID-19
COVID-19 Vaccines May Now Be Coadministered
- Las Vacunas contra COVID-19 Ahora Se Pueden Coadministrar
Clinical considerations for administering Pfizer-BioNTech COVID-19 vaccine to adolescents ages 12-15 years
Updated CMS and CDC Guidance for Visitation
Resuming Use of J&J COVID 19 Vaccine
- Reanudar el uso de la Vacuna J&J COVID 19
Adverse Event Reporting Following COVID-19 Vaccination
- Reportar Evento Adverso después de la recibir la Vacuna COVID-19
Overall Quarantine Guidance
- Orientación General sobre Cuarentena
Storage and Handling of COVID-19 Vaccines
Pause in Administration of Johnson & Johnson (Janssen) COVID-19 Vaccine
CDC Interim Public Health Recommendations for Fully Vaccinated Individuals
Implementation Considerations for the Janssen (Johnson & Johnson) COVID-19 Vaccine
- Consideraciones de Implementación para la Vacuna contra COVID-19 de Janssen (Johnson & Johnson) COVID-19
Quarantine Guidance for Vaccinated Persons
- Orientación de Cuarentena para Personas Vacunadas
Guidance on Vaccine Access for Nevadans with Underlying Health Conditions
- Actualización a la Orientación del Programa de Inmunización del Estado de Nevada sobre Acceso a la Vacuna para las personas de Nevada con condiciones de salud subyacentes
Placement of patients/residents who have been vaccinated against COVID-19 or who have had COVID-19 and have recovered
- Colocación de pacientes/ residentes que han sido vacunados contra COVID-19 o que han tenido COVID-19 y han recuperado
Moderna Vaccine Lot 41L20A and higher incidence of adverse reactions
COVID-19 Point of Care Antigen Testing
- Novedad: Pruebas de Antígeno en el Punto de Atención para COVID-19
Requirement for Hospitals to Report Ban on Medically Necessary Procedures
- Requisito para Hospitales Informar sobre la Prohibición de Procedimientos Medicamente Necesarios
CDC Updated Guidance for Reducing Quarantine Period for Contacts of Persons with COVID-19 Infection
Guidance for Discontinuation of COVID-19 Isolation
- Orientación sobre la suspensión del aislamiento de COVID-19
REMOVAL OF DIRECTIVE to Discontinue the Use of Antigen Testing in Skilled Nursing Facilities Until Further Notice
COVID-19 Laboratory Reporting Requirements
COVID-19 Point of Care Testing (8/28/2020)
Guidelines for Discontinuation of In-Home Isolation and Transmission-Based Precautions among Hospitalized Patients with COVID-19
Require Immediate Reporting of COVID-19 Test Results to the Nevada Division of Public and Behavioral Health
Multisystem Inflammatory Syndrome in Children (MIS-C) and Required Reporting for MIS-C
- Síndrome Inflamatorio Multisistémico en Niños (MIS-C) y Reportaje Requerido para MIS-C
Pharmacists and Medical Laboratory Testing Under the PREP Act - issued 06-02-2020
- Farmacéuticos y Prueba Médica de Laboratorio Bajo la Ley PREP
Expansion of COVID-19 Testing Criteria - issued 05-05-2020
- Ampliación de los Criterios de Prueba para COVID-19
- Laboratory Testing Frequently Asked Questions
Updated Testing Criteria for COVID-19 - issued 04-20-2020
Non-Physician Practitioners and Home Health Orders - issued 04-17-2020
- Practicantes No- Médicos y Órdenes de Atención Medica en el Hogar
Interim Guidance on Alternative, Improvised and Homemade Facemasks - issued 04-03-2020
Guidance for Health Care Personnel with Potential Exposure to COVID-19 Patients - issued 04-01-2020
Visitors' Guide to Health Care Facilities - issued 03-30-2020
COVID-19 Message to Employers - issued 03-27-2020
Home Health Personnel and Coronavirus Disease 2019 (COVID-19) - issued 03-23-2020
Updated Interim Testing Criteria for COVID-19 - issued 03-20-2020
Interim Guidelines for Discontinuation of In-Home Isolation and Transmission-Based Precautions among Hospitalized Patients with COVID-19 - issued 03-17-2020
COVID-19 Practices and Processes for Nevada Health Facilities - issued 03-16-2020
Reporting of Extraordinary Occurrence of Illness - issued 03-05-2020
CDC Updated Interim Infection Prevention & Control Recommendations for Patients with Known or Patients Under Investigation for 2019 Novel Coronavirus in a Healthcare Setting - issued 01-31-2020
Novel Coronavirus general information - issued 01-24-2020